Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 4, 2011, Pages 1029-1038

  Borbone, Eleonora ^a,c   Troncone, Giancarlo ^b,c   Ferraro, Angelo ^a,c   Jasencakova, Zuzana ^c,d   Stojic, Lovorka ^c,d   Esposito, Francesco ^a   Hornig, Nadine ^c,d   Fusco, Alfredo ^a,c   Orlando, Valerio ^c,d  

^a CNRS   (France)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c European School of Molecular Medicine   (Italy)

^d IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

POLYCOMB GROUP PROTEIN; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR PAX8;

ANAPLASTIC CARCINOMA; ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; THYROID CARCINOMA; TUMOR DIFFERENTIATION;

ANIMALS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HELA CELLS; HUMANS; MICE; MICE, TRANSGENIC; PAIRED BOX TRANSCRIPTION FACTORS; THYROID NEOPLASMS; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 79953862870     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-1784     Document Type: Article

References (40)

1. Kondo T, Ezzat S, Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292-306
2. World Health Organization 2004 Classification of tumours. In: DeLellisRA,LloydRV,Heitz PU, Eng C, eds. Pathology and genetics of tumours of endocrine organs. Lyon, France: IARC Press
3. Bracken AP, Helin K 2009 Polycomb group proteins: Navigators of lineage pathways led astray in cancer. Nat Rev Cancer 9:773-784
4. Simon JA, Kingston RE 2009 Mechanisms of polycomb gene silencing: Knowns and unknowns. Nat Rev Mol Cell Biol 10:697-708
5. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang Y 2002 Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298:1039-1043 (Pubitemid 35247314)
6. Czermin B, Melfi R, McCabe D, Seitz V, Imhof A, Pirrotta V 2002 Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal polycomb sites. Cell 111:185-196 (Pubitemid 35292439)
7. Kuzmichev A, Jenuwein T, Tempst P, Reinberg D 2004 Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. Mol Cell 14:183-193 (Pubitemid 38515646)
8. Hansen KH, Bracken AP, Pasini D, Dietrich N, Gehani SS, Monrad A, Rappsilber J, Lerdrup M, Helin K 2008 A model for transmission of the H3K27me3 epigenetic mark. Nat Cell Biol 10:1291-1300
9. Margueron R, Justin N, Ohno K, Sharpe ML, Son J, Drury 3rd WJ, Voigt P, Martin SR, Taylor WR, De Marco V, Pirrotta V, Reinberg D, Gamblin S 2009 Role of the polycomb protein EED in the propagation of repressive histone marks. Nature 461:762-767
10. Kirmizis A, Bartley SM, Kuzmichev A, Margueron R, Reinberg D, Green R, Farnham PJ 2004 Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev 18:1592-1605 (Pubitemid 38868910)
11. Kirmizis A, Bartley SM, Farnham PJ 2003 Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol Cancer Ther 2:113-121
12. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K 2003 EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22:5323-5335 (Pubitemid 37279943)
13. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, RotterV2004 Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 23:5759-5769 (Pubitemid 39093021)
14. Simon JA, Lange CA 2008 Roles of the EZH2 histone methyltransferase in cancer epigenetics Mutat Res 647:21-29
15. Karanikolas BD, Figueiredo ML, Wu L 2009 Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Mol Cancer Res 7:1456-1465
16. Pallante P, Berlingieri MT, Troncone G, Kruhoffer M, Orntoft TF, Viglietto G, Caleo A, Migliaccio I, Decaussin-Petrucci M, Santoro M, Palombini L, Fusco A 2005 UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas. Br J Cancer 93: 464-471 (Pubitemid 43080022)
17. Borbone E, Berlingieri MT, De Bellis F, Nebbioso A, Chiappetta G, Mai A, Altucci L, Fusco A 2010 Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene 29:105-116
18. Nappi TC, Salerno P, Zitzelsberger H, Carlomagno F, Salvatore G, Santoro M 2009 Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. Cancer Res 69: 1916-1923
19. Miyagishi M, Taira K 2003 Strategies for generation of an siRNA expression library directed against the human genome. Oligonucleotides 13:325-333 (Pubitemid 38404817)
20. Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT 2007 EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 67:547-556 (Pubitemid 46536947)
21. Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, Matese JC, Perou CM, Hurt MM, Brown PO, BotsteinD 2002 Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 13:1977-2000 (Pubitemid 34651487)
22. Breiling A, Turner BM, Bianchi ME, Orlando V 2001 General transcription factors bind promoters repressed by Polycomb group proteins. Nature 412:651-655
23. PierantoniGM,Rinaldo C, Esposito F, MottoleseM,Soddu S, Fusco A 2006 High mobility group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity. Cell Death Differ 13:1554-1563 (Pubitemid 44210358)
24. Russell JP, Powell DJ, Cunnane M, Greco A, Portella G, Santoro M, Fusco A, Rothstein JL 2000 The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium. Oncogene 19: 5729-5735
25. Vitagliano D, Portella G, Troncone G, Francione A, Rossi C, Bruno A, Giorgini A, Coluzzi S, Nappi TC, Rothstein JL, Pasquinelli R, Chiappetta G, Terracciano D, Macchia V, Melillo RM, Fusco A, Santoro M 2006 Thyroid targeting of the N-ras (Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. Oncogene 25:5467-5474 (Pubitemid 44330289)
26. Ledent C, Dumont J, Vassart G, Parmentier M 1991 Thyroid adenocarcinomas secondary to tissue-specific expression of Simian virus- 40 large T-antigen in transgenic mice. Endocrinology 129: 1391-1401
27. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, Kleer CG, Varambally S, Chinnaiyan AM 2008 Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 58:7274-7284
28. Fujii S, Ochiai A. 2008 Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci 99:738-746 (Pubitemid 351448078)
29. Pasca di Magliano M, Di Lauro R, ZanniniM2000 Pax8 has a key role in thyroid cell differentiation. Proc Natl Acad Sci USA 97: 13144-13149
30. Miccadei S, De Leo R, Zammarchi E, Natali PG, CivitarealeD2002 The synergistic activity of thyroid transcription factor 1 and Pax 8 relies on the promoter/enhancer interplay. Mol Endocrinol 16:837-846 (Pubitemid 34297751)
31. Fabbro D, Di Loreto C, Beltrami CA, Belfiore A, Di Lauro R, Damante G 1994 Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res 54: 4744-4749 (Pubitemid 24276506)
32. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, Fry B, Meissner A, Wernig M, Plath K, Jaenisch R, Wagschal A, Feil R, Schreiber SL, Lander ES 2006 A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125: 315-326
33. Sparmann A, van LohuizenM2006 Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6:846-856 (Pubitemid 44629896)
34. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar- Sinha C, SandaMG,Ghosh D, Pienta KJ, SewaltRG,Otte AP, Rubin MA, Chinnaiyan AM 2002 The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624-629
35. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, Yap D, Humphries RK, Griffith OL, Shah S, Zhu H, Kimbara M, Shashkin P, Charlot JF, Tcherpakov M, Corbett R,TamA, Varhol R, Smailus D, Moksa M, Zhao Y, Delaney A, Qian H, Birol I, Schein J, Moore R, Holt R, Horsman DE, Connors JM, Jones S, Aparicio S, Hirst M, Gascoyne RD, Marra MA 2010 Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal- center origin. Nat Genet 42:181-185
36. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP 1993. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179-184 (Pubitemid 23037270)
37. Salvatore G, Nappi TC, Salerno P, Jiang Y, Garbi C, Ugolini C, Miccoli P, Basolo F, Castellone MD, Cirafici AM, Melillo RM, Fusco A, Bittner ML, SantoroM2007 A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res 67:10148-10158 (Pubitemid 350070786)
38. WuZL, Zheng SS, LiZM,Qiao YY, AauMY,YuQ2010 Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ 17:801-810
39. Suvà ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino D, Cironi L, Marquez VE, Clément V, Stamenkovic I 2009 EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 69:9211-9218
40. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET,YuQ2007 Pharmacologic disruption of Polycombrepressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21:1050-1063 (Pubitemid 46686474)